Bead Biopharma is built upon three main pillars of potency, safety and enduring efficacy of novel and existing antibody-drug conjugate (ADC) therapeutics.
Bead has developed a suite of proprietary technologies in the ADC space. The resulting ADCs demonstrate enhanced characteristics and address multiple limitations of existing and novel therapeutics.
Bead has a unique ‘toolbox’ approach to design screen and develop ADCs with defined multiple drug loading.
